Intellia Therapeutics - NTLA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $128.00
  • Forecasted Upside: 127.35 %
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 15 Buy Ratings
  • 0 Strong Buy Ratings
▼ -3.17 (-5.33%)

This chart shows the closing price for NTLA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Intellia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTLA

Analyst Price Target is $128.00
▲ +127.35% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $128.00, with a high forecast of $182.00 and a low forecast of $54.00. The average price target represents a 127.35% upside from the last price of $56.30.

This chart shows the closing price for NTLA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 16 polled investment analysts is to buy stock in Intellia Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 19 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 19 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022Credit Suisse GroupBoost Target$101.00Low
8/5/2022SVB LeerinkLower TargetOutperform$155.00 ➝ $152.00Low
8/5/2022Chardan CapitalLower TargetBuy$172.00 ➝ $146.00Low
6/16/2022BMO Capital MarketsInitiated CoverageMarket Perform$54.00High
6/16/2022Bank of AmericaInitiated CoverageBuy$70.00Medium
5/24/2022The Goldman Sachs GroupLower TargetBuy$206.00 ➝ $180.00Low
5/9/2022OppenheimerLower Target$160.00 ➝ $130.00High
5/9/2022JMP SecuritiesLower Target$165.00 ➝ $110.00High
4/28/2022Credit Suisse GroupInitiated CoverageOutperform$100.00Medium
3/21/2022JMP SecuritiesReiterated RatingBuy$165.00High
3/7/2022Brookline Capital AcquisitionUpgradeHold ➝ Buy$91.00Low
3/7/2022Brookline Capital ManagementUpgradeHold ➝ Buy$91.00High
3/1/2022Chardan CapitalLower TargetBuy$177.00 ➝ $172.00High
3/1/2022Robert W. BairdLower Target$146.00 ➝ $83.00High
2/18/2022William BlairInitiated CoverageOutperform$144.00High
2/14/2022Brookline Capital AcquisitionInitiated CoverageHoldLow
2/14/2022Brookline Capital ManagementReiterated RatingBuyLow
2/7/2022OppenheimerUpgradeMarket Perform ➝ Outperform$145.00 ➝ $150.00High
1/31/2022CowenInitiated CoverageOutperformHigh
1/7/2022JMP SecuritiesLower TargetMarket Outperform$175.00 ➝ $165.00Low
1/7/2022Piper SandlerInitiated CoverageOverweight$171.00Low
11/5/2021OppenheimerLower TargetMarket Perform$160.00 ➝ $145.00Low
11/5/2021HC WainwrightBoost TargetBuy$171.00 ➝ $182.00Medium
10/21/2021HC WainwrightReiterated RatingBuy$172.00Medium
10/5/2021GuggenheimInitiated CoverageBuy$170.00Low
9/23/2021Stifel NicolausInitiated CoverageBuy$173.00High
9/16/2021Chardan CapitalReiterated RatingBuy$177.00Low
9/13/2021HC WainwrightReiterated RatingBuy$171.00Medium
8/6/2021JMP SecuritiesBoost TargetMarket Outperform$160.00 ➝ $175.00Medium
8/6/2021The Goldman Sachs GroupBoost TargetBuy$225.00 ➝ $252.00Medium
8/6/2021OppenheimerBoost TargetMarket Perform$125.00 ➝ $160.00Medium
8/6/2021Chardan CapitalBoost TargetBuy$130.00 ➝ $177.00Low
8/6/2021Raymond JamesBoost TargetOutperform$168.00 ➝ $181.00Low
8/5/2021Roth CapitalBoost TargetBuy$110.00 ➝ $180.00Medium
7/7/2021Chardan CapitalReiterated RatingBuyMedium
7/1/2021Robert W. BairdReiterated RatingHold$85.00High
6/29/2021OppenheimerBoost TargetMarket Perform$73.00 ➝ $125.00High
6/29/2021Raymond JamesBoost TargetOutperform$106.00 ➝ $168.00High
6/28/2021Royal Bank of CanadaBoost TargetOutperform$110.00 ➝ $150.00High
6/28/2021Truist FinancialBoost TargetBuy$80.00 ➝ $160.00High
6/28/2021WedbushBoost TargetNeutral$73.00 ➝ $87.00High
6/28/2021Roth CapitalBoost TargetBuy$80.00 ➝ $110.00High
6/28/2021The Goldman Sachs GroupBoost TargetBuy$115.00 ➝ $163.00High
6/28/2021BarclaysBoost TargetPositive ➝ Overweight$88.00 ➝ $134.00High
6/28/2021HC WainwrightBoost TargetBuy$111.00 ➝ $171.00High
6/26/2021Chardan CapitalBoost TargetBuy$85.00 ➝ $130.00High
6/23/2021Robert W. BairdBoost TargetPositive ➝ Neutral$60.00 ➝ $85.00High
6/23/2021JMP SecuritiesBoost TargetPositive ➝ Outperform$80.00 ➝ $88.00High
6/22/2021Jefferies Financial GroupBoost TargetBuy$83.00 ➝ $109.00High
6/22/2021HC WainwrightReiterated RatingBuy$111.00 ➝ $171.00Low
6/11/2021HC WainwrightInitiated CoverageBuy$111.00Medium
6/9/2021Raymond JamesReiterated RatingBuyLow
5/7/2021Roth CapitalUpgradeNeutral ➝ Buy$75.00 ➝ $80.00Medium
5/3/2021Royal Bank of CanadaInitiated CoverageOutperform$110.00Medium
3/21/2021SVB LeerinkReiterated RatingBuyHigh
3/4/2021JMP SecuritiesInitiated CoverageOutperform$80.00High
2/26/2021Truist FinancialBoost Target$40.00 ➝ $80.00High
2/10/2021Chardan CapitalBoost TargetBuy$57.50 ➝ $85.00Low
1/8/2021Raymond JamesBoost TargetOutperform$39.00 ➝ $106.00High
1/8/2021BarclaysBoost TargetOverweight$46.00 ➝ $90.00Low
12/22/2020Robert W. BairdDowngradeOutperform ➝ Neutral$60.00High
12/21/2020SVB LeerinkBoost TargetOutperform$27.00 ➝ $61.00High
12/7/2020Wells Fargo & CompanyBoost TargetOverweight$38.00 ➝ $52.00Medium
11/5/2020SVB LeerinkReiterated RatingOutperformMedium
10/27/2020Truist FinancialInitiated CoverageBuy$40.00 ➝ $40.00High
10/27/2020Summer StreetInitiated CoverageBuyHigh
10/19/2020Roth CapitalBoost TargetReduce ➝ Neutral$16.00 ➝ $26.00Low
10/14/2020Wells Fargo & CompanyInitiated CoverageOverweightMedium
9/30/2020OppenheimerReiterated RatingHoldHigh
9/18/2020The Goldman Sachs GroupInitiated CoverageBuy$33.00High
8/6/2020Chardan CapitalReiterated RatingBuyHigh
6/2/2020Credit Suisse GroupBoost TargetNeutral$19.00 ➝ $21.00High
6/1/2020WedbushBoost TargetNeutral$16.00 ➝ $20.00High
6/1/2020Chardan CapitalReiterated RatingBuy$57.50High
5/8/2020OppenheimerReiterated RatingHoldLow
4/2/2020BTIG ResearchReiterated RatingBuy$22.00Low
3/31/2020Chardan CapitalReiterated RatingBuy$57.50High
2/28/2020OppenheimerUpgradeMarket Perform ➝ OutperformHigh
2/14/2020WedbushDowngradeOutperform ➝ Neutral$21.00 ➝ $16.00High
2/10/2020Chardan CapitalReiterated RatingBuy$57.50Low
1/9/2020Chardan CapitalReiterated RatingBuy$57.50Medium
11/1/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$24.00High
9/27/2019Chardan CapitalSet TargetBuy$57.50High
7/8/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$23.00Medium
6/10/2019Roth CapitalInitiated CoverageNeutral$16.00High
5/28/2019Chardan CapitalReiterated RatingBuy$57.50Low
5/3/2019WedbushUpgradeNeutral ➝ Outperform$20.00 ➝ $21.00High
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
2/27/2019Chardan CapitalReiterated RatingBuy$57.50High
2/7/2019BTIG ResearchInitiated CoverageBuy$20.00High
11/27/2018SVB LeerinkInitiated CoverageOutperform$23.00High
11/2/2018WedbushDowngradeOutperform ➝ Neutral$36.00 ➝ $20.00Medium
10/31/2018OppenheimerReiterated RatingHoldHigh
10/29/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$24.00High
9/20/2018Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformHigh
8/24/2018Chardan CapitalReiterated RatingBuy$57.50Low
5/18/2018WedbushReiterated RatingOutperform$36.00High
5/15/2018Chardan CapitalUpgradeNeutral ➝ BuyHigh
3/15/2018WedbushReiterated RatingOutperform$36.00High
3/14/2018SVB LeerinkReiterated RatingOutperformHigh
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ OutperformHigh
3/7/2018BarclaysBoost TargetOverweight ➝ Overweight$33.00 ➝ $46.00Medium
12/18/2017OppenheimerReiterated RatingHoldLow
12/12/2017OppenheimerReiterated RatingHoldHigh
11/5/2017BarclaysReiterated RatingBuyN/A
11/3/2017Credit Suisse GroupBoost TargetOutperform$24.00 ➝ $28.00N/A
10/31/2017Jefferies Financial GroupSet TargetBuy ➝ Buy$36.00 ➝ $42.00N/A
10/31/2017SVB LeerinkBoost TargetOutperform$29.00 ➝ $37.00N/A
10/3/2017Jefferies Financial GroupReiterated RatingBuy$36.00High
9/27/2017WedbushReiterated RatingOurperform$29.00 ➝ $25.00High
9/6/2017BarclaysInitiated CoverageOverweight$29.00Low
8/29/2017Chardan CapitalDowngradeBuy ➝ Neutral$20.00High
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 6 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Intellia Therapeutics logo
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $56.30
Low: $56.21
High: $58.43

50 Day Range

MA: $58.74
Low: $38.49
High: $71.70

52 Week Range

Now: $56.30
Low: $37.08
High: $180.59


718,953 shs

Average Volume

1,208,102 shs

Market Capitalization

$4.28 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Intellia Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Intellia Therapeutics in the last year: Bank of America Co., BMO Capital Markets, Brookline Capital Acquisition Corp., Brookline Capital Management, Chardan Capital, Cowen Inc, Credit Suisse Group AG, Guggenheim, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Stifel Nicolaus,, SVB Leerink LLC, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for NTLA.

What is the current price target for Intellia Therapeutics?

16 Wall Street analysts have set twelve-month price targets for Intellia Therapeutics in the last year. Their average twelve-month price target is $128.00, suggesting a possible upside of 127.4%. HC Wainwright has the highest price target set, predicting NTLA will reach $182.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $54.00 for Intellia Therapeutics in the next year.
View the latest price targets for NTLA.

What is the current consensus analyst rating for Intellia Therapeutics?

Intellia Therapeutics currently has 1 hold rating and 15 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NTLA will outperform the market and that investors should add to their positions of Intellia Therapeutics.
View the latest ratings for NTLA.

What other companies compete with Intellia Therapeutics?

How do I contact Intellia Therapeutics' investor relations team?

Intellia Therapeutics' physical mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company's listed phone number is (857) 285-6200 and its investor relations email address is [email protected] The official website for Intellia Therapeutics is Learn More about contacing Intellia Therapeutics investor relations.